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 ABSTRACT 
PKCα AND CPI-17 EXPRESSION AND SPATIAL-TEMPORAL DISTRIBUTION 
WITH ACTIVATION IN PIG STOMACH ANTRUM AND FUNDUS 
 
Yu Zhang, B.S. 
 
Marquette University, 2010 
 
 
Smooth muscle contraction is a complicated process coordinated by 
contractile, regulatory and cytoskeletal proteins. The force generation depends on the 
phosphorylation of Myosin Regulatory Light Chain (MLC20). Myosin Light Chain 
Kinase (MLCK) and Myosin Light Chain Phosphatase (MLCP) are the two main 
regulators of the MLC20 phosphorylation level. MLCP is further controlled by two 
known pathways including the G protein coupled receptors (GPCRs)/ phospholipase 
C (PLC)/ diacylglycerol (DAG)/ protein kinase C (PKC)/ PKC-potentiated inhibitory 
protein for heterotrimeric myosin light chain phosphatase of 17 kDa (CPI-17) 
pathway. While messengers involved in this pathway have been proposed, studies on 
the details of the pathway are still controversial.  
 
This study explored the spatial-temporal regulation and distribution of PKCα 
and CPI-17 in intact animal tissues. Immunohistochemical results show that the 
distribution of PKCα in the longitudinal and circular layers of the fundus and antrum 
under relaxed conditions was predominantly localized at or near the periphery of the 
smooth muscle cell. Stimulation of the tissues with 1µM phorbol 12,13-dibutyrate 
(PDBu) for 10 or 30 minutes or 1µM carbachol (CCh) for 3 minutes does not alter the 
distribution pattern of PKCα. Different from PKCα, CPI-17 appeared to be 
“uniformly” distributed throughout the smooth muscle cells under relaxed conditions. 
 Stimulation of the tissues with 1µM PDBu or 1µM CCh for 30 minutes led to a 
significant distribution shift of CPI-17 from throughout the cytosol to primarily at the 
cell periphery. Results from double labeling of PKCα and vinculin/talin under relaxed 
condition or CPI-17 and vinculin/talin under stimulated condition suggested that 
PKCα and CPI-17 were not associated with the adherens junction. It is likely that 
PKCα and CPI-17 are localized at the caveolae on the plasma membrane. This study 
also revealed that the force generated in tonic fundus smooth muscle is much greater 
than that in phasic antrum tissue upon PDBu stimulation. Immunoblot analyses 
demonstrated that this difference was not caused by a difference in the expression of 
PKCα or CPI-17 between these two tissues.  
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CHAPTER I 
 
Introduction 
 
 
Possible mechanisms underlying phasic and tonic smooth muscle contraction 
 
Smooth muscle cells display heterogeneous expression and function of 
contractile, regulatory and cytoskeletal proteins. Various smooth muscle tissues 
express different proteins (or protein isoforms), which can modulate their contractile 
function. Based on their physiological responses, smooth muscles can be divided into 
tonic and phasic types (Somlyo, 1968). Tonic smooth muscles generate a slow steady 
isometric contraction that is maintained, while phasic smooth muscles develop a 
relatively fast transient isometric contraction. In general, visceral organs display 
primarily phasic contractions, while the vascular system generates predominantly 
tonic contractions. The tonic vascular smooth muscles such as aorta, femoral, and 
carotid arteries exhibit a graded force development followed by a well maintained 
contraction. In contrast to tonic smooth muscles, phasic muscles, such as stomach 
antrum, bladder, and ileum respond to agonist and generate a very fast but transient 
contraction. There are exceptions such as the phasic portal vein and vas deferens 
(both vascular) and the tonic fundus (visceral) smooth muscle. Studies by Himpens et 
al showed that the time course of [Ca2+]i is similar in both phasic and tonic muscle 
types - an initial transient increase to a peak value followed by a drop to 
approximately 70%  of its peak concentration upon high K+ treatment in tonic  
smooth muscles and to 60% in phasic smooth muscles (Himpens et al., 1988). Thus, 
the diversity of contraction pattern between tonic and phasic smooth muscle might 
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involve factors other than Ca2+ modulation. Several hypotheses have been proposed 
to explain the mechanism(s) responsible for tonic and phasic smooth muscle 
contractions. These include: 1) myosin heavy chain (MHC) isoforms SMA/B and 
myosin light chain (MLC) isoforms that are spatially distributed and temporally 
regulated in smooth muscle tissues. In addition, it has been widely reported that 
MLC17 and MLC20 isoforms are differentially expressed in smooth muscles  
(Cavaillé et al., 1986). It also has been shown that MHC SMA/B isoforms have 
unique expression pattern in tissues. SMB MHC primarily exists in phasic tissues like 
stomach antrum and bladder, whereas the SMA MHC isoform is predominantly 
expressed in tonic smooth muscle tissues, such as stomach fundus, and elastic arteries 
(Eddiger & Meer, 2007). 2) Smooth muscle cross-bridges called latch bridges could 
also contribute to the tonic force maintenance. It has been reported that the MgADP 
has a higher affinity to cross-bridges in tonic smooth muscle than in phasic smooth 
muscle slowing relaxation. Thus, the MgADP could uniquely affect smooth muscle 
contractile characters between these two muscle types, especially at low [Ca2+]i 
(Khromov et al.,1998; Dillon et al., 1981). 3) Proteins such as caldesmon or calponin, 
which may play an important role in forming actin-to-myosin cross links are also 
proposed to affect and regulate force generation (Sutherland & Walsh, 1989). 4) 
Regulation of actin polymerization/depolymerization has also been reported to be 
responsible for controlling the force development. Chen et al (Chen et al., 2008) 
reported that binding of myosin to actin can trigger actin polymerization and enhance 
the force development in arterial smooth muscle. 5) With the discovery of multiple G-
protein coupled receptors (GCPRs) and their downstream regulatory pathways in 
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smooth muscle contraction (Kitazawa & Somlyo, 1991b; Kubota et al., 1992), these 
pathways have been reported as additional important regulators of the different 
contractile responses in smooth muscle tissues (Khalil et al., 1992; Krymsky et al., 
2001; Woodsome et al., 2001). 
 
Regulation of Smooth muscle contraction pathways 
 Regulation of MLCK 
It is well accepted that the phosphorylation of MLC20 is a critical step leading 
to smooth muscle contraction (Murthy, 2006). While the steps following MLC20 
phosphorylation are thought to be the same for smooth muscle contraction under 
different conditions, two opposing mechanisms are proposed for regulating the 
phosphorylation level of MLC20 (Gong et al.,1992; Ito et al., 2003). A Ca2+ related 
process was reported to be responsible for phosphorylating MLC20 in smooth muscle 
activation. Identification of the Ca2+ binding protein calmodulin (CaM) and multiple 
other factors showed that the signal transduction is regulated by an interconnected 
intracellular pathway. The binding of Ca2+ /CaM on the catalytic domain of myosin 
light chain kinase (MLCK) activates its kinase activity and this activity was shown to 
be responsible for phosphorylating serine 19 on MLC20 to cause contraction 
(Kitazawa et al., 2000). A second pathway for controlling the degree of MLC20 
phosphorylation is Ca2+- independent and G-protein coupled. The key regulator in 
this pathway is myosin light chain phosphatase (MLCP) which is responsible for 
dephosphorylating MLC20. For decades, the importance of MLCP was 
underestimated because it was assumed that this enzyme is constitutively active. 
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However, recent work showed that MLCP is regulated in smooth muscle cells and its 
activity varies under different conditions (Gallagher et al., 1991; Ito et al., 2004). It 
has been reported that without affecting MLCK, inhibition of MLCP increases MLC20 
phosphorylation and in turn enhances force production at any given level of Ca2+  
(Hartshorne et al., 1998). The ratio of activity of MLCK to MLCP is believed to be 
the critical factor for MLC20 phosphorylation and force produced in smooth muscle 
contraction. The greater the ratio, the greater the force that can be generated. 
 
 Regulation of MLCP----RhoA/ROCK pathway 
Different from the MLCK regulation mechanism, the pathways controlling 
MLCP activity may be Ca2+-independent (Fig.1.1). MLCP is a protein with three 
subunits: a 38-kDa catalytic subunit of type 1 phosphatase (PP1cδ), a 110-kD 
noncatalytic myosin phosphatase-targeting subunit (MYPT1) and a 20-kDa 
noncatalytic subunit (M20) of unknown function. Second messengers interacting with 
different subunits of MLCP are proposed to be a major regulatory mechanism (Hori 
et al., 1993). Two major signal transduction pathways have been proposed to have the 
ability of regulating MLCP activity. One pathway is mediated by RhoA activated Rho 
kinase (ROCK) and this kinase is able to inhibit MLCP through phosphorylation of 
MYPT1 at Thr696 (Somlyo AP & Somlyo AV, 2003; Wang et al., 2009). 
Phosphorylated MYPT1 appears to have a reduced affinity for myosin and this 
decreases the catalytic activity of PP1cδ, which leads to the inhibition of MLCP to 
dephosphorylate MLC20. 
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Figure 1.1.  Mechanism of smooth muscle contraction. Two major pathways 
(PKC/CPI-17 pathway and RhoA/ROCK pathway) are involved in regulating the 
activity of MLCP. 
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Regulation of MLCP ---- PKC/CPI-17 pathway   
Another pathway proposed to be involved in controlling MLCP activity is the 
Protein Kinase C (PKC)–mediated PKC-potentiated inhibitory protein for  
heterotrimeric myosin light chain phosphatase of 17 kDa (CPI-17) pathway. CPI-17 is 
the first PP1cδ inhibitory protein identified in smooth muscle (Velasco et al., 2002).  
It has been reported that phosphorylation of CPI-17 on Thr-38 increases the 
phosphatase inhibitory potency more than 1000-fold (Eto et al.,1995). Although 
several kinases such as RhoA, ROCK and P21-activated protein kinase (PAK) have 
been shown to have the potential to phosphorylate CPI-17, PKC is believed to be the 
primary CPI-17 regulating kinase in smooth muscle in vivo (Eto et al., 1997; 
Kitazawa et al., 2003; Koyama et al., 2000). 
 
Studies show that PKC dependent pathways are initiated by agonist binding 
and a conformation change of G protein coupled receptors (GPCRs) (Somlyo AP & 
Somlyo AV, 1994). After binding with agonists, altered GPCR have the ability to 
activate G proteins. G proteins can significantly boost the activity of phospholipase C 
(PLC), which is in turn utilized by the cell to breakdown phosphatidylinositol 4,5-
bisphosphate (PIP2) into inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG). 
As a small soluble protein, IP3 can move to the sarcoplasmic reticulum (SR) and 
activate the IP3 receptors (IP3R) to release calcium. The released calcium partially 
contributes to the Ca2+- dependent pathway phosphorylating MLC20. At the same 
time, DAG remains in the cell membrane. PKC is activated through binding to DAG.  
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Figure 1.2.  PKC/CPI-17 pathway in smooth muscle contraction. With agonists 
stimulation, GPCR have the ability to activate G proteins. G proteins can significantly 
boost PLC activity, which are able to breakdown PIP2 into inostitol IP3 and DAG. IP3 
can move to sarcoplasmic reticulum and activate the IP3 receptor (IP3R) to open 
calcium channels. The released calcium partially contributes to the Ca2+-dependent 
pathway phosphorylating MLC20. At the same time, DAG remains in the cell 
membrane. PKC is activated through binding to DAG. Activated PKC binds to and 
phosphorylates CPI-17. Phosphorylated CPI-17 inhibits the function of MLCP and 
enhances smooth muscle contraction. 
 
Ca2+ 
agonist 
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Upon phosphorylation by PKC, CPI-17 inhibits the function of MLCP, and enhances 
smooth muscle contraction (Fig. 1.2). 
 
It is believed that PKC is regulated by its activation status via binding to DAG 
and spatial distribution within the cell. There are at least 10 PKC isoforms and they 
can be divided into 3 classes based on their homology: 1) classical PKCs subfamily 
(cPKCs) including PKCα, βII, and θ, whose activation is Ca2+, phospholipid,  and 
DAG dependent. 2) Novel PKCs (nPKCs) subfamily including PKCδ, ε, η, which 
require phospholipids and DAG but do not require calcium for activation. 3) Atypical 
PKC (aPKCs) subfamily including PKCλ, ζ and τ, which do not require DAG or 
calcium for activation (Reyland, 2009). It is also reported that both the inactive and 
active PKC isozymes are localized to specific sites because of the finding of several 
specific anchoring molecules named RICK (receptors for inactivated C-kinase) and 
RACK (receptors for activated C-kinase) (Mochly-Rosen, 1995; Mochly-Rosen & 
Gordon, 1998; Mochly-Rosen et al.,1991). In addition, it has been reported that the 
activation of persistent Ca2+ sparklets depend on the PKC binding (Navedo et al., 
2006; Navedo et al., 2005). Ca2+ sparklets result from activation of small clusters of 
L-type Ca2+ channels (LTCC) to create a continual Ca2+ influx. This suggests the 
particular localization of PKC might be near the membrane where LTCC are located. 
However, many studies suggest that PKC is diffusely distributed in the cytosol in 
relaxed conditions and upon stimulation translocates to the membrane (Secrest et al., 
1991; Li et al., 2002; Nakamura & Nishizuka, 1994). There are reasons to question 
these studies of spatial distribution and relative movement of these proteins. No 
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mechanism has been proposed of how the signal is transferred from the membrane 
embedded DAG to MLC20 which can be located throughout the cytosol. Besides PKC, 
CPI-17 and MLCP have also been reported to translocate from the cytosol to the 
membrane upon stimulation (Shin et al., 2002; Sakai et al., 2005). These two 
molecules are believed to be downstream factors of PKC in this pathway. However, 
close observation of experiments supporting the translocation of PKC, CPI-17 and 
MLCP reveals that most of these studies either employed indirect strategies or were 
done in isolated/cultured cell systems. Isolated cells may not be a reliable system to 
reflect the in vivo physiological situation. It has been reported that in vivo, the smooth 
muscle cells express a contractile phenotype, while isolated/cultured smooth muscle 
cells differentiate into a synthetic phenotype leading to a loss of contractile capability 
(Owens, 1995). Because it is well accepted that PKC is activated by newly generated 
DAG, which is a membrane bound phospholipid, and is a fairly large molecule 
(~77KD; Reyland, 2009), it might be more reasonable for PKC to stay near the 
membrane while other smaller messenger molecules translocate to and from the 
membrane. If this is the case, there must be at least one downstream factor working as 
a moving messenger to carry the signal from the membrane to the cytosol where 
MLC20 is located. So far, no molecule has been shown to perform this function. 
 
The aims and rationales of this study 
To avoid the potential limitations of isolated/cultured cell studies, this study 
was designed to observe the distribution of PKC and CPI-17 directly in intact tissues 
in relaxed and agonist stimulated conditions. Pig stomach tissue was selected to be 
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the model system. Because of its similarities to human, pigs have served as a research 
model to study physiology and signal transduction for decades. It has been shown that 
the pig genome and human genome have a high homology in sequence and 
chromosome structure (Lunney, 2007). Pigs are also a good source for organ 
transplantation to human (Dekel et al., 2003). Another advantage of using the pig 
stomach is that it is easily handled due to the relative large size, includes both tonic 
and phasic SM, and has relatively large smooth muscle cells, allowing for increased 
resolution with immunostaining. 
 
In this study, phorbol 12, 13-dibutyrate (PDBu) and carbachol (CCh) were 
used to activate the PKC pathway (Shimamoto et al.,1993). The advantage of using 
PDBu, an analog of DAG, is that it has the ability to directly initiate the PKC 
dependent pathway. PDBu can insert into the cell membrane and activate PKCα by 
binding to its N-terminal region (Kraft & Anderson, 1983). Although PDBu can 
efficiently activate the PKC pathway, it is not a physiological agonist. Therefore, 
CCh, a cholinergic agonist, which can stimulate both muscarinic and nicotinic 
receptors was also used in this study. The purpose of this study was to determine the 
protein expression levels and distribution of PKCα and CPI-17 under relaxed and 
stimulated conditions in intact phasic and tonic SM tissues. Li et al. (2002) reported 
that stimulating cultured smooth muscle cells with PDBu leads to a slow but robust 
translocation of PKCa from the cytosolic to the plasma membrane by observing with 
confocal microscopy. These results suggested that the translocation process starts 8 
min after PDBu treatment. Sakai reported that CPI-17 begins to translocate to the 
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membrane fraction after 2 min stimulation with Acetylcholine (Sakai et al., 2005). 
Based on these studies, the distribution of PKCα and CPI-17 were observed at 
multiple time points in this study to enhance the likelihood of observing translocation.  
 
Force measurement experiments previously done in our lab show that force 
generated in rabbit antrum after PDBu treatment is insignificant compared with the 
response of fundus.  This difference suggests diversity in the PKC pathway in the 
different stomach regions. If PKCα traslocates in a similar pattern in both of these 
stomach regions, the difference in their force generation is likely to be caused by 
other steps within this pathway or by other mechanisms. The expression level of CPI-
17 is not the same in different types (phasic vs. tonic) of smooth muscle tissue from 
rabbit, and tonic smooth muscle has more CPI-17 content than phasic smooth muscle. 
(Woodsome et al., 2001). Thus, this study measured PKC and CPI-17 protein 
expression in antrum and fundus to determine their potential impact on this pathway 
and on force generation. Surprisingly, no significant difference in the protein 
expression level of PKCα and CPI-17 was detected between the fundus and antrum. 
 
Summary 
In summary, this study was designed to determine the protein expression and 
spatial-temporal distribution of PKCα and CPI-17 in phasic stomach antrum and tonic 
stomach fundus under relaxed and activated conditions at multiple time points. Our 
results indicate that there is no significant difference in the level of protein expression 
of PKCα and CPI-17 between pig antrum and fundus. There is also no observable 
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translocation of PKCα in either relaxed or stimulated conditions in either tissue. 
PKCα is always located near the cell periphery. On the other hand, CPI-17 was 
observed to translocate from the cytosol to the plasma membrane upon stimulation 
(both PDBu and CCh). This translocation is very slow, requiring more than three 
minutes, and is not observed to return to basal conditions by 30 min of stimulation. 
Further studies need to be done to determine if and how the CPI-17 that is activated at 
the plasma membrane can regulate MLCP that is present in the cytosol. 
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CHAPTER II 
 
Materials and Methods 
 
 
Organ and tissue handling 
Swine tissues (stomachs) were obtained from Hansen Meat Service (Franksville, 
WI) and put in cold physiological salt solution (PSS (in mM): 140.1 NaCl, 4.7 KCl, 
1.2 Na2HPO4, 2.0 MOPS (pH 7.4), 0.02 Na2EDTA, 1.2 MgSO4, 1.6 CaCl2, and 5.6 
glucose). Stomachs were cleaned of blood, loose connective tissue, and in some cases, 
the mucosa, and frozen in isopentane cooled in liquid nitrogen or stored in PSS in the 
refrigerator for 0-2 days. Some organs were fresh frozen as soon as possible 
following post-mortem (60-90 minutes). Some organs were incubated in PSS or 
stimulated with 1.0 µM CCh or PDBu (Sigma) for different time points prior to rapid 
freezing. Variable incubation times and agonist concentrations were also tested. All 
tissue was stored frozen until sectioned and immunoreacted. Five to ten µm sections 
of the frozen tissues were cut on a Leica CM1900 cryostat, picked up on glass slides 
and stored frozen (0-1 days).  
 
Immunoreactions 
Reagents. The antibodies used were obtained from the following sources: PKCα 
(H-7 and C-20), CPI-17(H-60) from Santa Cruz Biotech, Santa Cruz CA; Vinculin 
and Talin from Sigma, Saint Louis, Missouri; Cy2 and Cy3 Donkey anti-mouse or 
rabbit secondary antibodies from Jackson ImmunoResearch, West Grove, PA; Alexa 
Fluor 594-phalloidin and DAPI from Molecular Probes, Eugene, OR.  
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Frozen tissue sections picked up on glass slides were fixed with 2% 
paraformaldehyde for 10 minutes, permeabilized in 0.5% Triton X-100 for 10 
minutes and blocked with 5mg/ml BSA for 1 hour prior to incubating with the 
primary antibody overnight and then the appropriate secondary antibody for one hour 
at room temperature. After the secondary antibody, the tissues were incubated with 
DAPI (0.5 µM), phalloidin (10-50 nM) or DAPI/phalloidin as appropriate for staining 
nuclei and/or filamentous actin. Three washes were used following the primary and 
secondary incubations, and the counterstaining. Cover glasses were mounted using 
buffered 75% glycerol with 0.2% n-propyl gallate to minimize fading. All 
immunoreacting solutions were made in PBS-Tween [(in g/liter: NaCl 8.0, KH2PO4 
0.2, Na2HPO4 1.15, KCl 0.2,), 1% tween-20, pH 7.4] with 0.1% BSA. Negative 
controls included 0.1%BSA leaving out the primary antibody. 
 
Microscopy. Sections were observed using an Olympus IX70 microscope with 
epifluorescence illumination. Digital images were taken with a 16bit Princeton 
Instruments (Princeton, NJ) CCD camera, controlled through a PCI board via IPLab 
for Windows on a PC (Ver. 3.6, Scanalytics; Fairfax, VA).  Images using a 100x (1.3 
NA) objective were taken. Emission filters used were 405, 490 and 570 nm. Sections 
were also viewed using a Nikon confocal microscope (Nikon A1 confocal eclipse ti). 
The objectives used were 100X(1.4NA) oil lens at 425,488 and 561 nm.  Similar 
results were observed in immunofluorescence distributions using these two different 
systems.  
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Image Analysis of protein distribution of single cells in tissues 
Profiles of fluorescence intensity were taken for individual cells in transverse 
tissue sections. Sections were observed at low magnification (10-20x) to avoid areas 
of apparent artifacts (tissue folding, freeze damage, etc). In an artifact free area the 
magnification was increased to 40-100x, and pictures were taken at 100x. Three 
different areas within one section were chosen to take pictures. Z-stack series were 
taken individually for each of the three color channels used. 1µm thick Z sections 
were taken, and 10-15 Z sections were taken for each tissue section. Each Z stack 
series was examined for each section to identify the center z image, and this image 
was converted to a .bmp file, which was imported to NIS-Elements AR 3.0 (Nikon) 
on a PC to analyze the data.   
 
Image Analysis of distribution of PKC/CPI-17 of individual Cells in tissues.   
Profiles of PKCα and Phalloidin fluorescence intensity were obtained for 
individual cells in transverse tissue sections. A line was drawn across the center of the 
image. Ten cells crossed by the line were selected for measurements. Based on our 
previous protocols (25), the first five pixels (~0.7µm) on either side of the cell where 
the phalloidin intensity increased sharply from baseline were defined as the periphery 
of the cell. For cytosolic measurements, a line was placed at least 2 µm away from 
the cell periphery. Intensity measurements were made using a region of interest (ROI) 
roughly at the center of the cell (for cytosolic measurements), or along the cell’s 
membrane (for peripheral measurements). For consistency, the ROI is kept constant 
for the peripheral and cytosolic measurements.  Cells in the section with very small 
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diameters (not able to measure cytosolic ROI at least 2 µm from the periphery) or 
with nuclei present (visible DAPI staining; spatial limitations and perinuclear 
organelles could confound the distribution) were excluded from analysis. For PKCα, 
the ratio of the average intensity of PKCα at the periphery over the total PKCα 
intensity (sum of PKCα intensity from ROI at periphery and ROI in cytosol) was used. 
Ten cells per field and three different fields were subjected to measurement for data 
analysis for each tissue region, i.e. thirty cells were counted and averaged for each 
sample (n = 1). The final sample size is n=5.The same procedures were applied to 
measure the intensity of CPI-17, except that only one field of 10 cells were used for 
each sample (n = 1), with a final sample size of n=3.  
 
Mechanical measurements 
Immediately before use, tissue strips were cut and clamped on each end, with the 
clamps secured between hooks on a stationary metal rod and an isometric force 
transducer (Harvard Apparatus, Holliston, MA), in PSS bubbled with 95% O2/5% 
CO2 in water-jacketed muscle chambers (Radnoti Glass Technology, Monrovia, CA) 
at 37oC. The length of each strip was varied by repositioning of the stationary metal 
rod. 
 
Smooth muscle tissue strips (stomach antrum and fundus) were equilibrated for 
1 h and stretched to a passive tension approximating Lo using an abbreviated length-
tension curve. To contract tissues, PSS was replaced with K+-PSS (109 mM KCl and 
70 mM NaCl substituted for 140 mM NaCl). The muscle strip was activated 
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repeatedly with stretching of the tissue between each activation, until peak force no 
longer showed a significant increase over the previous contraction. Chambers were 
flushed three times with PSS following each tissue activation. At least two successive 
K+-PSS contractions were used to get a standard force trace with a 10 minute rest 
between each contraction before starting the experiment. The tissues were then 
activated with 1 µM carbachol and relaxed again as for the K+-PSS contractions. 
Subsequent contractions all included 1 µM phentolamine and propranolol to block α 
and β adrenergic receptors, respectively.  Following the final 1 µM CCh contraction 
and wash, the tissues were activated with 1µM PDBu to record their mechanical 
response. 
 
Analysis of Force Data.  Voltage signals from force transducers were digitized 
by PowerLab 400 or 4SP hardware (ADInstruments, Castle Hill, Australia) visualized 
on a computer screen (Chart v3.6 or 4.0, ADInstruments) as force (g) at 10 Hz and 
stored by software command to a hard disk for later analyses. Analyses were 
performed using the chart software and figures were made with the spreadsheet 
program Excel 2000 (Microsoft, Redmond, WA).  
 
Gel Electrophoresis and western blotting 
Protein expression was analyzed as described previously (Han et al., 2006). 
Tissues were homogenized in 0.125 M Tris, 2% sodium dodecylsulfate (wt/vol), 20% 
glycerol, 0.1% bromophenol blue (wt/vol) and 20 mM dithiothreitol. Proteins were 
resolved on low cross-linking sodium dodecylsulfate gels (Giulian et al., 1983) and 
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immunoblotting was performed as previously described (Eddinger & Wolf, 1993). 
Western immunoblots were performed as reported previously (Gaylinn et al., 1989). 
 
Statistics 
 Statistical comparisons were carried out using MINITAB (Minitab Inc. State 
College, PA).  A one sample t-test was used to test the distribution of PKCα/CPI-17 
(peripheral ROI content vs. total ROI content = 0.5 indicating a “uniform” 
distribution in the SMCs) in antrum and fundus under resting condition. One way 
ANOVA was performed to test for PKC/CPI-17 distribution differences for the two 
tissues with different stimulating parameters. Two sample t-tests were used to test the 
significance of difference for expression level of PKC or CPI-17 in Antrum and 
Fundus. A value of P< 0.05 was considered significant. 
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CHAPTER III 
 
Results 
 
 
 
Swine stomach fundus is a tonic smooth muscle tissue that responds to 
stimulation with a sustained contraction while the antrum is a phasic smooth muscle 
tissue that responds to stimulation with a transient contraction (Fig. 3.1). In tissues, 
these responses are a result of direct stimulation of the smooth muscle tissue as 
addition of 1 µM propranolol (β agonist blocker) and phentolamine (α agonist 
blocker), which prohibit neuronal activation via these pathways. Stimulation of 
smooth muscle with PDBu is used routinely to stimulate PKC and cause smooth 
muscle contraction via PKC activation. 1 µM PDBU causes a small slow contraction 
in stomach fundus strips (~40% of K+ stimulation response) while the antrum shows 
essentially no response (<5% K+ stimulation) (Fig. 3.1). The difference between the 
responses of these two tissues to PDBu stimulation could be due to expression and/or 
spatial-temporal distribution of the downstream second messengers (PKCα and CPI-
17) that are purported to be responsible for MLCP inhibition with PDBu stimulation. 
To examine this we measured the expression levels and determined the spatial-
temporal distribution of PKCα and CPI-17 protein in these tissues.  
 
Figure 3.2 shows western blot results of the expression of CPI-17 and PKCα 
in the stomach antrum and fundus. Tissues were processed to control for 
concentration, and the results were calculated based on the intensity of the signal and 
by normalizing to actin protein expression levels. Both methods indicate that neither 
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the expression of CPI-17 nor that of PKCα is significantly different between these 
two smooth muscle tissues. Controls were done using a range of loadings in both 
antrum and fundus tissues to confirm the range of linearity of loading and that 
samples used for quantitation were within this range (Fig. 3.3). Because there are no 
differences in the expression for these two proteins between these two tissues, we 
proceeded to determine if differences in their spatial-temporal distribution could 
explain the difference in their responses to agonist stimulation. 
 
Figures 3.4 and 3.5 show immuohistochemical results for the distribution of 
PKCα in the longitudinal and circular layers of the fundus (Fig. 3.4) and antrum     
(Fig. 3.5). Under resting conditions in relaxing solution when there is no force 
generation by the tissue, the PKCα appears to be uniquely distributed near the 
periphery of the smooth muscle cells (Fig. 3.4 & 3.5 – PSS). Stimulation of the 
tissues with 1 µM PDBu (10 and 30 minutes) or 1µM CCh (3 minutes) does not alter 
this primarily peripheral distribution of PKCα. The ratio of the distribution of the 
PKCα near the plasma membrane relative to that in total was used to quantify 
possible changes in the distribution of this protein under these different conditions. 
Figure 3.6 shows the results as the ratio of the PKCα at the cells periphery relative to 
the total PKCα  present in the cell (periperhal/ (peripheral + cytosol), see methods). A 
ratio of 0.5 would indicate a “uniform” distribution of the protein throughout the cell. 
The PKCα ratio (peripheral/total) ranged from 0.64 – 0.68 in all the conditions 
examined. These values are significantly greater than 0.5, indicating that PKC is 
located primarily at the cells periphery (it is not “uniformly” distributed in the cell) 
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and that their distribution does not change between the relaxed or stimulated 
conditions.  
 
Because PKCα is proposed to activate CPI-17, we proceeded to determine the 
spatial-temporal distribution of CPI-17 in these tissues under these same conditions. 
Figures 3.7 & 3.8 show immuohistochemical results for the distribution of CPI-17 in 
the longitudinal and circular layers of the fundus (Fig. 3.7) and antrum (Fig. 3.8). 
Under resting conditions in relaxing solution when there is no force generation by the 
tissue, CPI-17 appears to be “uniformly” distributed throughout the smooth muscle 
cells (Fig. 3.7 & 3.8 – PSS). Stimulation of the tissues with 1 µM PDBu (30 minutes) 
or 1µM CCh (30 minutes) results in a significant change in this distribution such that 
the CPI-17 now appears to be primarily at the periphery of the cell in a distribution 
similar to that observed for PKCα. The ratio of the distribution of the CPI-17 near the 
plasma membrane relative to total CPI-17 (peripheral + cytosolic) was used to 
quantify possible changes in the distribution of this protein under these different 
conditions. Figure 3.9 shows the results as the ratio of the CPI-17 at the cells 
periphery as a ratio of the CPI-17 total protein.  The CPI-17 ratio (peripheral/total) 
ranged from 0.49– 0.67 in all tissues and conditions examined. The ratio of CPI-17 
peripheral/total in relaxed conditions is not significantly different than 0.5 (means 
0.49 – 0.5; P > 0.19) indicating that the CPI-17 is “uniformly” distributed throughout 
the smooth muscle cells under this condition. This does not change following 3 
minutes of 1 µM CCh stimulation as there is still no significant difference from the 
relaxed conditions (means = 0.53 – 0.55; P > 0.05) with the exception of the fundus 
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tissues where the CPI-17 peripheral/total ratio is significantly greater (p < 0.05) at 3 
minutes. With 30 minutes of either 1 µM CCh or 1 µM PDBu stimulation, the CPI-17 
distribution becomes significantly greater than 0.5 for  all tissue and layers, (means = 
0.62 – 0.67, P < 0.01), indicating that CPI-17  is now located primarily at the cells 
periphery (it is no longer “uniformly” distributed in the cell), similar to the 
distribution of PKCα (Fig. 3.4 & 3.5).  
 
The primarily peripheral distribution of PKCα (under both relaxed and 
stimulated conditions) and CPI-17 (following 30 minutes stimulation with CCh or 
PDBu) is not uniform at the cell periphery, but punctuate in distribution (Fig. 3.10). 
There is also a punctuate distribution of the anatomically and functionally distinct 
adherens junctions and caveolae at the smooth muscle cell plasmalemma (Eddinger et 
al., 2007). In order to determine if the punctuate distribution of the PKCα and CPI-17 
at the membrane corresponds with the punctuate pattern of the adherens junctions, we 
did double labeling with two adherens junction associated proteins, vinculin and talin. 
The double labeling of PKCα with talin/vinculin in relaxed condition and CPI-17 
with talin/vinculin under stimulated condition was performed. The results show that 
PKCα and CPI -17 do not co-localize with either vinculin or talin, suggesting that 
PKCα and CPI-17 do not associate with the adherens junction complex with the 
relaxed or activated conditions we examined.  
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Figure 3.1.  Force (normalized to peak force from KPSS stimulation) 
generated by stimulating with KPSS, CCh, or PDBu in fundus (grey) and 
antrum (black). Antrum contractile response is not maintained during the 
stimulation while that in the fundus is. PDBu generated a slow contraction in 
the fundus that is ~ 40% of its peak KPSS force, but caused little to no 
contraction in the antrum. Deflections in the traces at the start of each wash are 
from changing the solution in the chambers.  
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Figure 3.2.  Protein expression of CPI-17 and PKCα in fundus and antrum. 
A: western blot results of CPI-17 (left) and PKC (right) expression in fundus and 
antrum with actin (coomassie blue stain) expression for each sample shown below. 
B: Quantitative data of western blot results. Protein expression level of CPI-17 
(left) and PKCα in fundus and antrum normalized to actin expression. The 
expression level of PKCα and CPI-17 were not significantly different between the 
fundus and antrum. 
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Antrum actin  
Fundus actin  
Antrum PKC    Fundus CPI-17 
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Antrum CPI-17 Fundus CPI-17 
Figure 3.3.  Quantitation of PKC and CPI-17 in antrum (A,C) and in fundus (B,D). A and 
B, loading series from 4µl to 20 µl of swine antrum and fundus extract (50mg tissue:1ml 
buffer) was subjected to SDS-PAGE. Total Actin was detected by coomassie blue and 
PKC and CPI-17 were detected by Western blotting. C and D, signal intensity plotted 
against amount of extract loaded for PKC and CPI-17 Western blots, and Coomassie 
Blue-stained actin, showing the linear relationship between the amount of sample loaded 
and the detected signal intensity. (n=3) 
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   Figure 3.4.  Confocal images of PKCα distribution in transverse sections of the 
longitudinal (left) and circular layer (right) of pig stomach fundus under relaxed (PSS) 
or stimulated (3 min CCh or 10min & 30 min PDBu) treatments. Tissues were 
immunoreacted for PKCα (green) and counterstained for phalloidin (red) and DAPI 
(blue). In all conditions, PKCα is located predominantly at the cell periphery near the 
plasma membrane. Scale bar - 10µm. 
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Figure 3.5.  Confocal images of PKCα distribution in transverse sections of the 
longitudinal (left) and circular layer (right) of pig stomach antrum under relaxed 
(PSS) or stimulated (3min CCh  or 10min & 30min PDBu) treatments. Tissues 
were immunoreacted for PKCα (green) and counterstained for phalloidin (red) 
and DAPI (blue). In all conditions, PKCα is located predominantly at the cell 
periphery near the plasma membrane. Scale bar - 10µm. 
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Figure 3.6.  Quantitative results of the ratio of the PKCα at the cells periphery 
to the total PKCα (peripheral + cytosolic) in the circular and longitudinal 
layers of the antrum and fundus. The ratio in relaxed condition (PSS) in both 
layers of antrum and fundus is significantly greater than 0.5, indicating a 
preferential distribution of PKCα near the plasma membrane in the relaxed 
condition. This ratio does not change significantly with different stimulation 
treatments, suggesting that PKCα maintains a primarily peripheral distribution 
in the cell at all times. (n=5) 
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Figure 3.7.  Confocal images of CPI-17 distribution in transverse sections of the 
longitudinal (left) and circular layer (right) of pig stomach fundus under relaxed 
conditions (PSS) or stimulated (CCh 30min or PDBu 30min) treatments. Tissues were 
immunoreacted for PKC (green) and DAPI (blue). In relaxed condition (PSS), CPI-17 
appears “uniformly” distributed in the cell, but with either CCh or PDBu stimulation, 
CPI-17 appears predominantly located at the periphery near the plasma membrane. 
Scale bar - 10µm. 
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Figure 3.8.  Confocal images of CPI-17 distribution in transverse sections of the 
longitudinal (left) and circular layer (right) of pig stomach antrum under relaxed 
conditions (PSS) or stimulated (CCh 30min of PDBu 30min) treatments. Tissues 
were immunoreacted for PKC (green) and DAPI (blue). In relaxed condition 
(PSS), CPI-17 appears “uniformly” distributed in the cell, but with either CCh or 
PDBu stimulation, CPI-17 appears predominantly located at the periphery near 
the plasma membrane. Scale bar - 10µm. 
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Figure 3.9.  Quantitative results of the ratio of the CPI-17 at the cells periphery 
to the total CPI-17 (peripheral + cytosolic) in the circular and longitudinal layer 
of the antrum and fundus. The ratio in the relaxed condition (PSS) in both layers 
of antrum and fundus is not significantly different than 0.5, indicating a uniform 
distribution of CPI-17 throughout the cells. Three minutes of CCh stimulation 
does not change the ratio of CPI-17 except in the fundus circular layer. Both 
CCh (30min) and PDBu (30min) treatments cause a significantly redistribution 
of CPI-17 to the cell periphery near the plasma membrane (ratios are 
significantly greater than 0.5). * p<0.05, **p<0.01 (n=3) 
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     CPI-17 and Talin 
Figure 3.10.  Confocal images of pig Fundus in relaxed condition (top) and 
with PDBu (30min) stimulation (bottom). Double labeling for PKCα (green) 
with vinculin (red, upper left) or talin (red, upper right) or CPI-17 (green) 
with vinculin (red, lower left) or talin (red, lower right). Vinculin and talin 
are adherens junction associated proteins that appear to have an alternating 
distribution with PKC and CPI-17, suggesting that these proteins are not 
localized to the same domains near the plasma membrane. Note that not all 
of the PKCα or CPI-17 is located near the plasma membrane.   
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CHAPTER IV 
Discussion 
Smooth muscle contraction is a complex activity, which involves multiple 
factors including contractile, cytoskeletal and regulatory proteins. Many questions 
regarding the molecular pathways participating in the contraction mechanism are still 
unclear. So far, several regulatory pathways have been reported to control smooth 
muscle contraction. In all of these pathways, Ca2+ is considered to be a primary factor, 
and elevating [Ca2+]i will enhance force generation through the activation of MLCK. 
As a “suppressor”, MLCP also plays a significant role in controlling the smooth 
muscle contraction. Several pathways can regulate MLCP and this regulation plays a 
key role in determining contractile force in smooth muscle (Ito et al., 2004; 
Hartshorne et al., 1998; Somlyo AP & Somlyo AV, 2003; Pfitzer G, 2001). In fact, 
the inhibition of MLCP activity is important for controlling Ca2+ sensitization 
(Kitazawa & Somlyo, 1991b; Somlyo AP & Somlyo AV, 2003). 
 
Studies on PKC distribution 
One of the proposed pathways to regulate MLCP is PKC dependent and 
messengers within the process include GPCR, PLC, DAG, PKC and CPI-17. 
Numerous publications have reported on the role of this pathway in regulating force 
production in smooth muscle. However, studies on the spatial distribution and relative 
movement of PKC and CPI-17 remain controversial. The debate focuses on how the 
signal is transferred from DAG, which is located primarily at the cell membrane, to 
myosin (MLC20) which can be detected throughout the cytosol (Parisi & Eddinger, 
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2002). To explain the signal transduction process, many hypotheses have been 
developed. One hypothesis suggests that PKC works as a moving messenger to relay 
the signal from the membrane to the cytosol. PKC, a member of a large family of 
serine/threonine kinases, was first identified in 1977 by Nishizuka’s group (Inoue et 
al., 1977; Takai et al., 1977). The first study on PKC localization by Kraft suggested 
that in EL4 mouse thymoma cells, the high level of PKC concentration within the 
cytosol could be reduced after phorbol ester stimulation (Kraft & Anderson, 1983). 
Following this study, numerous research groups reported translocation of PKC 
isoforms during certain cell activities using different techniques. The ability of PKC 
to move within a cell was further studied in the following three decades (Miyamoto et 
al., 1995; Nakamura & Nishizuka, 1994; Secrest et al., 1991). 
 
Biochemical analysis of PKC translocation 
Much of the evidence supporting the translocation of PKC during smooth 
muscle cell activation was obtained using biochemical studies. By using cellular 
fractionation on smooth muscle tissue, Diamond’s group explored PKC distribution 
within the bovine tracheae. They tested the enzymatic activity of generic PKC from 
membrane and cytosolic fractions to infer the distribution of the protein (Langlands & 
Diamond, 1992; Langlands & Diamond, 1994).  Their results suggest that PKC 
activity is higher in the cytosolic fraction than the membrane fraction under relaxed 
conditions while after methacholine stimulation, the situation was reversed. This 
activity shift was used as evidence for PKC translocation in their study. However, a 
change of PKC enzymatic activity is not a direct way to determine the distribution 
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shift of PKC and the two are not necessarily consistent with each other. Agonists 
could simply increase PKC enzymatic activity in a specific region of the cell without 
transferring additional PKC molecules from one location to another. To further 
explore this issue and elucidate possible PKC movement within cells, western 
blotting was used to study the PKC protein distribution in the bovine tracheae. It has 
been shown that in relaxed conditions, the concentration of PKCα and PKCβ in the 
pellet (membrane) fraction is the same as in the supernatant (cytosolic) fraction (the 
ratio of pellet to supernatant is ~1), while upon stimulation with PDBu, the ratio 
increased to ~3. This result suggests that administration of PDBu leads to the 
translocation of PKCα/β from the cytosol to the membrane (Hai & Kim, 2005). In 
addition, PKC translocates from the cytosol to the membrane in Rat Stomach Fundus 
upon PDBu treatment with similar methods (Secrest et al., 1991).  However, it is 
possible that the homogenization process used might alter the protein distribution 
between these fractions, and may not distinguish between membrane fractions 
(plasmalemmal, nuclear, mitochondrial, SR). Direct observation of the PKC 
distribution in cells using immunohistiochemical reactions allows direct visualization 
of protein location and distribution. 
 
Analysis of PKC tanslocation in isolated smooth muscle cells 
Immunofluorescence microscopy provides a chance to observe potential PKC 
movement within cells directly. Freshly isolated smooth muscle cells were used as a 
model to study translocation of PKC using immunocytochemistry. To obtain isolated 
single cells, collagenase and elastase were used to digest rat uterine smooth muscle 
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(Taggart et al., 1999). Isolated single cells were subjected to fixation and 
immunostaining and then observed with confocal microscopy to determine if the PKC 
distribution shifts upon different agonist stimulation. The results from this study 
showed that PKCα underwent a process of relocation from the cytosol to the plasma 
membrane after either CCh or phorbolester12-deoxyphorbol13-isobutyrate20-acetate 
(DPBA) incubation. The average ratio of PKC between peripheral to cytosolic was 
1.05 with relaxed conditions but increased to 2.09 following CCh stimulation. DPBA 
activation produced an even bigger shift of PKC distribution and the ratio was 2.77. It 
also has been reported that in relaxed rat arterial smooth muscle single cells PKCα 
was uniformly distributed throughout the cytosol, but after incubation with uridine 
triphosphate (UTP), PKCα moved towards and accumulated adjacent to the plasma 
membrane (Nelson et al., 2008). Similar changes in isolated rat colon smooth muscle 
cells after ceramide stimulation have also been shown (Ibitayo et al., 1999). Cultured 
cells were also used to determine the distribution of PKC with cell activation. 
Translocation of PKC from the cytosol to cell membrane in response to PDBu in 
cultured smooth muscle cells has been suggested (Li et al., 2002). At the same time, 
by using western blotting in isolated single cells, a concentration change of PKC in 
the particulate fraction of digested rabbit rectosigmoid smooth muscle cells before 
and after ceramide activation has also been observed (Bitar et al., 2002). However, 
while their results were statistically significant, the total ratio change was less than 
5%. The relevance of such a small shift causes one to question the importance of such 
a translocation of PKCα with a physiological function. On the other hand, there is 
also evidence to support a movement of PKC in the opposite direction. Fay’s group 
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reported that in isolated toad stomach single cells, a pool of activated PKC was 
identified adjacent to the plasma membrane. Upon stimulation with CCh, activated 
generic PKC was released from the pool and redistributed throughout the cytosol. 
Further study showed that PKC became associated with contractile filaments after the 
treatment (Meininger et al., 1999).   
 
Since freshly isolated or cultured smooth muscle cells are easy to obtain and 
handle, this experimental model is very popular and widely used. However, studies 
suggest that the phenotype of isolated or cultured smooth muscle cells are not 
necessarily the same as smooth muscle cells within tissues or organs. When smooth 
muscle cells are extracted from intact tissue, structure and functionality can be altered 
compared with that of cells in vivo (Owens, 1995). Cultured cells can also develop 
properties different from when they are associated in their in vivo condition. While 
smooth muscle cells in vivo show a contractile phenotype, isolated and cultured 
smooth muscle cells change with time to a synthetic phenotype. Results obtained 
from experiments of isolated single cells might be a consequence of alterations of cell 
structure and protein expression from the cell isolation procedure and/or from 
culturing. To eliminate potential changes that can occur in isolated cells compared 
with multicellular preparations, intact tissues were used in this study to determine 
PKC distribution in smooth muscle cells during relaxation and contraction. 
Surprisingly, the PKC distribution was not “uniform” throughout the cell in resting 
conditions and was not changed upon stimulation in intact tissues. PKC was primarily 
distributed adjacent to membrane, before and after PDBu or CCh treatment (Fig. 3.4 
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& 3.5). The pattern of PKC distribution was measured at multiple time points and it 
was always primarily at the cell periphery. Since PKC is a fairly large protein, it 
seems logical and efficient for the cell to keep it restricted to one place rather than to 
have it moving within the cell as a means of regulation. 
 
PKC binding proteins in relaxed condition 
It is easy to understand the attachment of PKC to cell membrane under 
stimulation since DAG is generated during the process. Newly produced DAG is 
membrane bound and it could work as a bridge to link PKC to the cell membrane 
after PKC is activated. However the accumulation of PKCα at the cell periphery 
under resting condition observed in this study raises a question about the primarily 
peripheral distribution of PKCα when DAG is absent. Since there is no evidence to 
support PKC as a membrane embedded protein, it is reasonable to speculate other 
membrane associated proteins binding to PKC under resting conditions and 
preventing it from randomly diffusing throughout the cell. Several proteins have been 
proposed to have the ability to hold PKC adjacent to cell membrane. The first two 
candidates, talin and vinculin were identified in the focal contact domain in 
nonstimulated fibroblasts and in cultured renal cells. It was reported that in cultured 
cells, PKCα could also be detected in focal contact structures and might bind to talin 
or vinculin (Dong et al., 1993). In this study, immunohistochemical methods were 
used to determine the relationship between PKCα and these two candidate proteins 
under more physiological conditions. Double labeling of PKC with talin or vinculin 
in intact swine stomach tissues (this study) shows a lack of association between PKC 
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and talin or vinculin suggesting that PKCα is not associated with the adherens 
junction. The PKCα appears near the plasmamembrane in an alternate punctuate 
pattern with either vinculin or talin (Fig. 3.10). Previous studies in our lab and others 
show that talin and vinculin are distributed alternately with caveolae at the plasma 
membrane (Eddinger et al., 2007; North et al., 1993; Tanaka et al., 2001). Thus it is 
possible that PKCα is associated with caveolae as it does not colocalize with talin and 
vinculin at the adherens junction. It is also possible that it moves from one of these 
domains to the other during cell activation. 
 
Several other studies suggest PKC could be a resident protein in a membrane 
structure called caveolae (Smart et al., 1994; Smart et al., 1995). Studies have 
identified multiple caveolae associated proteins as having the potential to bind to 
PKC. For instance, a 68kD PKCα binding protein termed serum deprivation response 
(sdr) was localized in caveolae (Mineo et al., 1998). Taggart et al also reported that 
PKCa has a particular amino acid sequence (522WAYGVLLY528) in the catalytic 
domain which has the potential of interacting with the scaffolding domain of 
Caveolin-1, a resident protein in caveolae (Taggart et al., 2000). The results from in 
vitro assays suggested caveolin-1 has an inhibitory effect on PKC. Sucrose gradient 
centrifugation also showed Caveolin-1 and PKC were accumulated in the same 
fraction, which could indicate an interaction between the two proteins (Oka et al., 
1997).  
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Membrane receptors termed RICKs and RACKs were also proposed to be 
able to interact with inactivated or activated PKC. (Mochly-Rosen, 1995; Mochly-
Rosen & Gordon, 1998; Mochly-Rosen et al., 1991). Their function is expected to 
maintain PKC in distinct locations on or near the cell membrane. One of these 
scaffolding proteins, AKAP150, has been reported to be able to target PKC to unique 
plasmalemmal domains where L-type Ca2+ channels are located. The contact between 
PKC and Ca2+ channels was suggested to be required for generating constitutive Ca2+ 
influx (Santana & Navedo, 2009). This is consistent with the observation that a 
population of L-type Ca2+ channels is localized to caveolae in ventricular myocytes 
since PKC was also expected to reside in the same location (Balijepalli et al., 2006). 
It seems logical to propose that PKC is anchored by caveolae associated protein to the 
cell membrane where it can be activated by DAG. Our data showing that PKCα does 
not co-localize with vinculin or talin is consistent with this idea. 
 
Studies on CPI-17 distribution 
While many membrane bound proteins were proposed to be able to hold PKC 
to the cell periphery, no candidate protein has been reported to bind CPI-17, the 
immediate downstream effecter of PKC, at the plasma membrane under resting 
conditions. Since PKC is supposed to interact with CPI-17 only when it is activated, 
CPI-17 is expected to be uniformly distributed throughout the cell in the absence of 
stimulation. Result from this study confirmed a “uniform” distribution pattern of CPI-
17 in stomach SMCs under relaxed condition. Unlike PKC, CPI-17 is only 17 KD and 
should easily move throughout the cell due to its fairly small size. Thus, it is 
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reasonable to propose a translocation of CPI-17 from the cytosol to the membrane 
upon stimulation. Activated PKC could act to sequester free CPI-17 from the cytosol 
and thus causes a passive translocation of CPI-17 from the cytosol to the membrane.  
The spatial-temporal regulation on CPI-17 in bronchial smooth muscle of rats under 
acetylcholine (ACh) stimulation using biochemical methods has been examined 
(Sakai et al., 2005). Immunoblotting experiments revealed a time-dependent shift of 
CPI-17 from the cytosol to the membrane upon stimulation. The movement started 
after 2 minutes of incubation with ACh and lasted for at least 18 minutes. To further 
study the possible translocation of CPI-17 and eliminate potential concerns 
introduced by cellular fractionation, this study examined CPI-17 movement in 
stomach antrum and fundus in intact tissue using Immunofluorescence microscopy. 
The results suggest that after stimulation with CCh or PDBu, the “uniform” 
distribution of CPI-17 was altered and the protein moved towards the membrane in a 
time dependent manner. This is consistent with the observation reported by Sakai et al 
(Sakai et al., 2005). Our study also revealed a punctuate distribution of CPI-17 at the 
membrane after stimulation. This suggests CPI-17 specifically accumulates to a 
particular membrane location. Considering CPI-17 is activated by PKC on the 
membrane, and PKCα appears to localize with caveolae, it is logical to propose that 
CPI-17 migrates specifically to caveolae upon stimulation. To eliminate the 
possibility that CPI-17 was associated with the adherens junction, co-localization 
between CPI-17 and talin/vinculin was also examined in this study. Double labeling 
was performed on CPI-17 and talin/vinculin which are resident proteins at the 
adherens junction. The results show an alternating punctuate distribution between 
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CPI-17 and talin/vinculin. Based on this observation, it is likely that CPI-17 and PKC 
colocalize at the caveolae on the cell membrane. While CPI-17 has been observed to 
translocate from the cytosol to the membrane upon stimulation (Fig. 3.7 & 3.8), there 
is still 40% CPI-17 remaining in the cytosol (Fig. 3.9). The distribution of CPI-17 
was parallel with actin in human pulmonary artery endothelial cell suggesting a co-
localization of CPI-17 and actin (Kolosova et al., 2004). Thus it is possible that when 
CPI-17 is in the cytosol, it associates with actin filaments. Moreover, a certain 
amount of CPI-17 has been located adjacent to the nucleus. This is consistent with the 
observation that PKCα can translocate to the perinuclear region and into the nucleus 
in vascular smooth muscle cells under stimulation (Haller et al., 1998). 
 
Signal transduction between CPI-17 and MLCP 
As one of the major regulatory mechanisms of Ca2+ sensitization, the  
PKC/CPI-17 pathway is only effective when it is able to block the downstream 
MLCP, which in turn lessens the response of the smooth muscle cell to Ca2+. MLCP 
is reported to be diffusely distributed throughout the cytosol (Shin et al., 2002).  If 
PKC is activated and localized at the membrane and CPI-17 translocates to the 
membrane to be activated by PKC, then a link between the peripheral CPI-17 and 
diffusely distributed MLCP needs to be identified. Several possible ways can be 
proposed to explain the signal transduction between CPI-17 and MLCP. One of them 
is that CPI-17 is translocated back from membrane to the cytosol after activation and 
interacts with MLCP in the cytosol. If this is the case, it is a slow process, since  
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CPI-17 was localized primarily at the cell membrane for at least 30 minutes after 
CCh/PDBu stimulation (Fig. 3.7& 3.8). A second possible explanation would be that 
there is another protein involved in this pathway, working as a bridge between CPI-17 
and MLCP. However, studies have shown that CPI-17 has the ability to directly 
inhibit MLCP, suggesting that it is unlikely for an additional messenger molecule to 
exist (Eto et al., 2004). A third possibility is that MLCP translocates upon stimulation 
from the cytosol to CPI-17 at the membrane and gets inactivated or is simply kept 
away from its substrate, MLC20 (Shin et al., 2002; Ogut & Brozovich, 2003). 
However, the fact that permeabilized smooth muscle cells do not seem to lose MLCP, 
suggests that MLCP is not a freely diffusing molecule in the cytosol. Other soluble 
proteins such as CPI-17 tend to diffuse out of cells when they are permeabilized (Eto 
et al., 1995; Eto et al., 1997). Thus, it seems unlikely for MLCP, if it is a bound 
protein in the cytosol, to diffuse freely towards the cell membrane. A more likely 
possibility would be that CPI-17 stays at the membrane after activation and inhibits 
only the MLCP localized near the cell periphery. This is consistent with the 
observation that [Ca2+]i is often elevated near the cell membrane region (Jonas & 
Zelck, 1974; Chen et al, 1991; Poburko et al, 2004). Since the main function of the 
PKC/CPI-17 pathway is to control Ca2+ sensitization of smooth muscle cells, it would  
be more effective for the regulation to be applied where [Ca2+]i  is high. 
 
Differences between tonic and phasic smooth muscle 
This study revealed that the PKC/CPI-17 pathway might not be equally 
significant for different types of smooth muscle in regulating contraction activity. 
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While PDBu caused a slow contraction in the fundus which is ~40% of the KPSS 
induced peak force, little contraction was generated in the antrum with PDBu 
stimulation. Since fundus and antrum represent two basic types of smooth muscle, 
tonic and phasic respectively, it seems logical to ascribe the difference in force 
generation to alternate distinct properties of phasic and tonic muscle. The expression 
level of CPI-17 in tonic smooth muscle is higher than that in phasic subtypes 
(Woodsome et al., 2001). This could be used to explain the different ability of tonic 
muscles to maintain force (CPI-17 inhibits MLCP allowing MLC20 phosphorylation 
to stay high and force to be maintained), but their study was limited to rabbit vascular 
muscle. This study examined CPI-17 expression in the visceral swine stomach. 
Surprisingly, no significant difference in the protein expression level of CPI-17 was 
detected between the fundus and antrum (Fig. 3.2). This result indicates that the 
difference between tonic and phasic smooth muscle in responding to PDBu treatment 
cannot be explained by CPI-17 level in all types of smooth muscle tissues. 
Measurement of PKC expression level with western blotting performed in this study 
also revealed no significant difference between tonic and phasic smooth muscle (Fig. 
3.2). Immunostaining confirmed the similarity between the two muscle types for CPI-
17 and PKC expression. Thus, alternative explanations are required. One possibility is 
that the different responses to PDBu were caused by differences in basal Ca2+ level 
between tonic and phasic smooth muscle. It was shown that tonic tissues have a 
higher level of [Ca2+]i than phasic tissues under relaxed conditions (Himpens et al., 
1988). It is possible that although PDBu administration could boost Ca2+ sensitization 
in phasic smooth muscle to a similar level as in tonic tissues, the low basal level of 
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[Ca2+]i might still not be able to maintain a strong contraction in phasic tissues. The 
differences of SR distribution in the two types of tissues may be responsible for 
differences in the [Ca2+]i in  basal conditions (Nixon et al., 1994). A second 
possibility would be that expression patterns of MLCP are different between tonic 
and phasic smooth muscle and this difference leads to differences in contraction to 
PDBu stimulation. This is supported by the observation that phasic smooth muscle 
contains more MLCP than tonic tissues (Woodsome et al., 2001). The above 
explanations are not necessarily exclusive to each other and the cause for differences 
in force generation may be the combination of the two.  
 
Conclusion 
As a tissue responsible for the contractility of all hollow organs, smooth muscle 
is under intensive study since it is important for maintenance of the normal function 
of many vital systems in organisms. In addition, many diseases are related to defects 
in the regulation of smooth muscle contraction. Elucidation of the regulatory 
mechanism for smooth muscle contraction under physiologically relevant conditions 
is therefore very important. As a major regulatory pathway in smooth muscle 
contraction, the PKC/CPI-17 signal transduction cascade requires thorough 
examination in physiologically relevant conditions. This study is the first to directly 
assess the expression and spatial- temporal regulation of the PKC/CPI-17 pathway in 
intact animal tissues. Immunostaining was used to determine the distribution patterns 
of PKC and CPI-17. In contrast with earlier studies, which were performed with 
isolated/cultured SMCs, this study reports that with or without smooth muscle cell 
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activation, PKCα is always preferentially localized near the plasma membrane, where 
it does not co-localize with vinculin or talin and thus is most likely associated with 
the caveolae (Fig. 4.1). Upon cell excitation, it is likely that the activated PKC 
acquires the ability to sequester free CPI-17 from the cytosol to the plasma membrane 
and therefore induce a shift of CPI-17 from the cytosol to the cell membrane. Based 
on the lack of co-localization of CPI-17 with vinculin/talin, I propose that CPI-17 
migrates and attaches to PKCα at the caveolae with stimulation. Membrane 
associated CPI-17 is reported to be activated by PKC and blocks the activity of 
MLCP. We were unable to observe CP-17 shift back to the cytosol in a 
physiologically relevant time frame, and thus propose that it only inhibits MLCP 
located in close proximity to the cell periphery (Fig. 4.2). This inhibition would lead 
to an increased Ca2+ sensitization and increased force generation in tonic smooth 
muscle. However, PDBu has little effect on phasic smooth muscle, which is not 
caused by expression variances of PKC and CPI-17. Differences in response to PDBu 
between the two tissues may be caused by differences of MLCP expression and/or 
basal [Ca2+]i levels.  
 
 
 
 
 
 
 
                                                                                                                                            51 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PIP2 
G 
protein 
A 
CPI-17 
MLCP 
Ca2+ 
PLC 
PKC 
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figure, “A” is used to represent one of such proteins. CPI-17 and MLCP are diffusely 
distributed in the cytosol under these conditions. 
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Figure 4.2.  A model for the spatial distribution of PKCα and CPI-17 under stimulated 
condition. With agonist stimulation, GPCR have the ability to activate G proteins. G proteins 
can significantly boost PLC activity, which hydrolyses PIP2 into inostitol IP3 and DAG. DAG 
remains in the cell membrane. PKCα is activated through binding to DAG (A). Activated PKC 
acquires the ability to sequester free CPI-17 from the cytosol and therefore induces a movement 
of CPI-17 from the cytosol to the cell membrane (B). PKC bounded CPI-17 gets activated by 
PKCα and further blocks the activity of MLCP located adjacent to cell periphery and enhances 
smooth muscle contraction by decreasing the cytosolic free MLCP (C). 
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